European Commission Approves Enhanced Wegovy Ob...

By João L. Carapinha

February 18, 2026

European Commission Backs Wegovy Obesity Treatment with 7.2 mg Dose The European Commission has approved a higher 7.2 mg maintenance dose of
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Surge in Obesity Intervention Costs in the Netherlands
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
Weight Loss: Advances in Hormone-Based Obesity Treatments
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Obesity Health Economics: Forecasting Trends and Costs in the US
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Impact of Generic Liraglutide Launch on Weight Management and Health Economics